Department of Radiation Oncology, University Hospital Zurich, Zurich, Switzerland.
Radiat Oncol. 2011 Jan 5;6:1. doi: 10.1186/1748-717X-6-1.
To evaluate the objective and subjective long term swallowing function, and to relate dysphagia to the radiation dose delivered to the critical anatomical structures in head and neck cancer patients treated with intensity modulated radiation therapy (IMRT, +/- chemotherapy), using a midline protection contour (below hyoid, ~level of vertebra 2/3).
82 patients with stage III/IV squamous cell carcinoma of the larynx, oropharynx, or hypopharynx, who underwent successful definitive (n = 63, mean dose 68.9Gy) or postoperative (n = 19, mean dose 64.2Gy) simultaneous integrated boost (SIB) -IMRT either alone or in combination with chemotherapy (85%) with curative intent between January 2002 and November 2005, were evaluated retrospectively. 13/63 definitively irradiated patients (21%) presented with a total gross tumor volume (tGTV) >70cc (82-173cc; mean 106cc). In all patients, a laryngo-pharyngeal midline sparing contour outside of the PTV was drawn. Dysphagia was graded according subjective patient-reported and objective observer-assessed instruments. All patients were re-assessed 12 months later. Dose distribution to the swallowing structures was calculated.
At the re-assessment, 32-month mean post treatment follow-up (range 16-60), grade 3/4 objective toxicity was assessed in 10%. At the 32-month evaluation as well as at the last follow up assessment mean 50 months (16-85) post-treatment, persisting swallowing dysfunction grade 3 was subjectively and objectively observed in 1 patient (1%). The 5-year local control rate of the cohort was 75%; no medial marginal failures were observed.
Our results show that sparing the swallowing structures by IMRT seems effective and relatively safe in terms of avoidance of persistent grade 3/4 late dysphagia and local disease control.
评估头颈部癌症患者接受调强放疗(IMRT,+/- 化疗)后客观和主观的长期吞咽功能,并将吞咽困难与关键解剖结构的放射剂量相关联,这些结构使用中线保护轮廓(舌骨下方,~第 2/3 椎体水平)。
82 例 III/IV 期声门、口咽或下咽鳞状细胞癌患者,2002 年 1 月至 2005 年 11 月,成功接受根治性(n = 63,平均剂量 68.9Gy)或术后(n = 19,平均剂量 64.2Gy)同期加量调强放疗(SIB-IMRT),单独或联合化疗(85%),均为治愈性目的。回顾性评估所有患者。63 例根治性放疗患者中有 13 例(21%)总肿瘤体积(tGTV)>70cc(82-173cc;平均 106cc)。在所有患者中,在 PTV 之外的咽-喉中线保护轮廓外画出。吞咽困难根据主观患者报告和客观观察者评估仪器进行分级。所有患者均在 12 个月后重新评估。计算吞咽结构的剂量分布。
在重新评估时,中位随访时间为 32 个月(范围 16-60),10%的患者评估为 3/4 级客观毒性。在 32 个月的评估以及最后一次随访评估(中位随访时间为 50 个月,范围 16-85 个月)中,1 名患者(1%)主观和客观观察到持续性 3 级吞咽功能障碍。该队列的 5 年局部控制率为 75%;未观察到内侧边缘失败。
我们的结果表明,通过 IMRT 保护吞咽结构在避免持续性 3/4 级晚期吞咽困难和局部疾病控制方面是有效且相对安全的。